GT Biopharma

GTM-104 is a stereotactic radiation therapy program sponsored by GT Biopharma for the treatment of glioblastoma. The program represents a non-pharmaceutical therapeutic modality classified as 'other' in development. As of the latest milestone dated April 10, 2025, the program status is listed as terminated, despite being designated as approved in phase classification. The program is associated with clinical trial NCT05900908. GT Biopharma's development strategy appears focused on radiation-based interventions for CNS malignancies, with stereotactic approaches representing a precision oncology methodology. The termination status as of April 2025 indicates the program is no longer actively advancing. No mechanism of action, specific target, or lead investigator information has been disclosed. Peak sales projections and consensus positioning remain undisclosed.

Glioblastoma represents one of the most aggressive primary brain malignancies with poor prognosis and limited treatment options. The disease carries significant unmet medical need, with median overall survival remaining suboptimal despite standard-of-care multimodal therapy. Stereotactic radiation techniques offer potential for enhanced precision in tumor targeting while minimizing collateral damage to surrounding healthy brain tissue, a critical consideration in CNS oncology. The competitive landscape for glioblastoma includes multiple phase 3 candidates and approved therapies, indicating active investment in this indication. However, the terminated status of GTM-104 suggests the program did not advance to commercial viability or met development challenges. The glioblastoma market remains clinically significant given the disease's high mortality rate and the ongoing need for improved therapeutic options. Patient populations affected are typically adults with newly diagnosed or recurrent disease, representing a limited but critically underserved market segment. Commercial significance is constrained by the small patient population but elevated by the severity of disease and willingness to pursue aggressive interventions.

GTM-104 is classified as a stereotactic radiation therapy, representing a physical/radiation-based modality rather than a pharmaceutical agent. The program components include radiation therapy and stereotactic delivery mechanisms. Specific molecular targets, mechanism of action details, and route of administration are not yet disclosed. Related therapeutic approaches in the competitive space include small-molecule chemotherapies (temozolomide, lomustine), targeted agents (cediranib, enzastaurin), immunotherapies (dendritic cell immunotherapy, ICT-107), and radiopharmaceuticals (131I-TLX-101-003). Patent status and first approval date are not disclosed in available intelligence.

• Modality: Stereotactic Radiation Therapy (non-pharmaceutical)
• Indication: Glioblastoma
• Sponsor: GT Biopharma
• Development Status: Terminated as of April 2025
• Associated Trials: NCT05900908 (primary), NCT06126705, NCT05783076, NCT05979792, NCT06238336

Regulatory approval status for GTM-104 is not yet clearly disclosed. The program is designated as 'approved' in phase classification but simultaneously marked as 'terminated' in status as of April 10, 2025, creating ambiguity regarding actual regulatory standing. FDA, EMA, PMDA (Japan), and NMPA (China) approval history is not disclosed. Associated clinical trials show regulatory activity in China (NMPA) with NCT06126705, NCT05783076, NCT05979792, and NCT06238336 listed as clinical trial registrations. Expected loss-of-exclusivity dates are not disclosed. The termination status suggests the program is no longer pursuing regulatory advancement or commercial development.

• FDA Status: Not yet disclosed
• EMA Status: Not yet disclosed
• PMPA (Japan) Status: Not yet disclosed
• NMPA (China) Status: Clinical trials ongoing (NCT06126705, NCT05783076, NCT05979792, NCT06238336)
• Program Status: Terminated as of April 10, 2025

GTM-104 represents GT Biopharma's investment in precision radiation oncology for glioblastoma, a disease with significant clinical need but limited therapeutic options. The program's termination as of April 2025, despite approved classification, suggests either strategic deprioritization, development challenges, or commercial viability concerns. The existence of GTM-103 (also approved, GT Biopharma) in the same indication raises questions about cannibalization or sequential development strategy.

Competitive positioning: The glioblastoma market includes 12+ competing programs across multiple modalities (small molecules, immunotherapies, radiopharmaceuticals, combination approaches). The crowded landscape and GTM-104's termination suggest stereotactic radiation therapy alone may not offer sufficient clinical or commercial differentiation versus established standards and emerging combination approaches.

Strategic implications: GT Biopharma's portfolio includes both GTM-103 and GTM-104 in glioblastoma, suggesting a multi-modal approach strategy. The termination of GTM-104 may reflect resource reallocation toward GTM-103 or other pipeline assets. Future catalysts are not evident given terminated status. Expected milestones are not disclosed. The lack of disclosed trial results, mechanism details, and regulatory pathway clarity limits assessment of scientific rationale for termination.

• Program termination suggests development challenges or strategic reprioritization
• Competitive crowding in glioblastoma space may have influenced decision
• Internal competition with GTM-103 may have influenced resource allocation
• Lack of disclosed clinical data limits assessment of scientific merit